Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

This study has been terminated.
(In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety concerns. As a result, the companion trial, OSI-774-206 has been stopped)
Information provided by (Responsible Party):
Astellas Pharma Inc ( OSI Pharmaceuticals ) Identifier:
First received: November 23, 2010
Last updated: July 16, 2015
Last verified: July 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: September 2012
  Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)